Novel drugs targeting sphingolipid metabolism

Handbook of Experimental Pharmacology

Volumn 215, Issue , 2013, Pages 187-196

  Bhabak, Krishna P ^a   Arenz, Christoph ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Drugs; Enzyme assays; Enzyme inhibitors; Natural products; Small molecules

Indexed keywords

3,3' (1,4 PHENYLENE)BIS[N [4 (4,5 DIHYDRO 1H IMIDAZOL 2 YL)PHENYL]ACRYLAMIDE]; AMITRIPTYLINE; B 13; C 11AG; CERAMIDASE; CERAMIDE; DESIPRAMINE; DEXAMETHASONE; DIHYDROCERAMIDE DESATURASE; ENZYME; ENZYME INHIBITOR; FINGOLIMOD; FUMONISIN B1; GALBONOLIDE A; GT 11; IMIPRAMINE; ISOFAGOMINE; KHAFREFUNGIN; MANUMYCIN A; MIGLUSTAT; SCYPHOSTATIN; SERINE PALMITOYLTRANSFERASE; SPHINGOLACTONE 24; SPHINGOLIPID; SPHINGOMYELIN PHOSPHODIESTERASE; SPIROEPOXIDE; THERMOZYMOCIDIN; TRICYCLO[4.3.0.1]DECAN 9 YL XANTHOGENATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; DRUG APPROVAL; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HUMAN; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPHINGOLIPID METABOLISM; ANIMAL; DRUG ANTAGONISM; METABOLISM; REVIEW;

ANIMALS; ENZYME INHIBITORS; HUMANS; SPHINGOLIPIDS; SPHINGOMYELIN PHOSPHODIESTERASE;

MLCS; MLOWN;

EID: 84880417882     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-7091-1368-4_10     Document Type: Article

References (46)

1. Adibhatla RM, Hatcher JF, Gusain A (2011) Tricyclodecan-9-yl-xanthogenate (D609) mechanism of actions: a mini-review of literature. Neurochem Res. doi:10.1007/s11064- 011-0659-z
2. Albouz S, Hauw JJ, Berwald-Netter Y, Boutry JM, Bourdon R, Baumann N (1981) Tricyclic antidepressants induce sphingomyelinase deficiency in fibroblast and neuroblastoma cell cultures. Biomedicine 35:218-220
3. Amtmann E (1996) The antiviral, antitumoural xanthate D609 is a competitive inhibitor of phosphatidylcholine-specific phospholipase C. Drugs Exp Clin Res 22:287-294
4. Amtmann E, Zoller M (2005) Stimulation of CD95-induced apoptosis in T-cells by a subtype specific neutral sphingomyelinase inhibitor. Biochem Pharmacol 69:1141-1148
5. Amtmann E, Zoller M, Schilling G (2000) Neutral sphingomyelinase- inhibiting guanidines prevent herpes simplex virus-1 replication. Drugs Exp Clin Res 26:57-65
6. Amtmann E, Baader W, Zoller M (2003) Neutral sphingomyelinase inhibitor C11AG prevents lipopolysaccharide-induced macrophage activation. Drugs Exp Clin Res 29:5- 13
7. Arenz C (2010) Small molecule inhibitors of acid sphingomyelinase. Cell Physiol Biochem 26:01-08
8. Arenz C, Giannis A (2000) Synthesis of the first selective irreversible inhibitor of neutral sphingomyelinase. Angew Chem Int Ed 39:1440-1442
9. Arenz C, Thutewohl M, Block O, Waldmann H, Altenbach HJ, Giannis A (2001) Manumycin A and its analogues are irreversible inhibitors of neutral sphingomyelinase. Chembiochem 2:141-143
10. Bai A, Meier GP, Wang Y, Luberto C, Hannun YA, Zhou D (2004) Prodrug modification increases potassium tricyclo[5.2.1.0(2,6)]-decan-8-yl dithiocarbonate (D609) chemical stability and cytotoxicity against U937 leukemia cells. J Pharmacol Exp Ther 309:1051- 1059
11. Bai A, Szulc ZM, Bielawski J, Mayroo N, Liu X, Norris J, Hannun YA, Bielawska A (2009) Synthesis and bioevaluation of ω-N-amino analogs of B13. Bioorg Med Chem 17:1840- 848
12. Bedia C, Casas J, Garcia V, Levade T, Fabriàs G (2007) Synthesis of a novel ceramide analogue and its use in a high-throughput fluorogenic assay for ceramidases. Chembiochem 8:642-648
13. Bielawska A, Greenberg MS, Perry D, Jayadev S, Shayman JA, McKay C, Hannun YA (1996) (1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol as an inhibitor of ceramidase. J Biol Chem 271:12646-12654
14. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, Aradhye S, Burtin P(2010) Fingolimod (FTY720): discovery and development of an oral drug to treat multiplesclerosis. Nat Rev Drug Discov 9:883-897
15. Canals D, Perry DM, Jenkins RW, Hannun YA (2011) Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases. Br J Pharmacol 163:694-712
16. Delgado A, Casas J, Llebaria A, Abad JS, Fabrias G (2006) Inhibitors of sphingolipid metabolismenzymes. Biochim Biophys Acta 1758:1957-1977
17. Devlin CM, Leventhal AR, Kuriakose G, Schuchman EH, Williams KJ, Tabas I (2008) Acid sphingomyelinase promotes lipoprotein retention within early atheromata and accelerates lesion progression. Arterioscler Thromb Vasc Biol 28:1723-1730
18. Elojeimy S, Holman DH, Liu X, El-Zawahry A, Villani M, Cheng JC, Mahdy A, Zeidan Y, Bielawska A, Hannun YA, Norris JS (2006) New insights on the use of desipramine as an inhibitor for acid ceramidase. FEBS Lett 580:4751-4756
19. Fan JQ (2003) A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends Pharmacol Sci 24:355-360
20. Grijalvo S, Bedia C, Triola G, Casas J, Llebaria A, Teixido J, Rabal O, Levade T, Delgado A, Fabriàs G (2006) Design, synthesis and activity as acid ceramidase inhibitors of 2- oxooctanoyl and N-oleoylethanolamine analogues. Chem Phys Lipids 144:69-84
21. Hemsley KM, Hopwood JJ (2011) Emerging therapies for neurodegenerative lysosomal storage disorders - from concept to reality. J Inherit Metab Dis 34:1003-1012
22. Kolter T, Sandhoff K (1999) Sphingolipids-their metabolic pathways and the pathobiochemistry of neurodegenerative diseases. Angew Chem Int Ed 11:1532-1568
23. Kolter T, Proia RL, Sandhoff K (2002) Combinatorial ganglioside biosynthesis. J Biol Chem 277:25859-25862
24. Kölzer M, Arenz C, Ferlinz K, Werth N, Schulze H, Klingenstein R, Sandhoff K (2003) Phosphatidylinositol-3,5-bisphosphate is a potent and selective inhibitor of acid sphingomyelinase. Biol Chem 384:1293-1298
25. Kornhuber J, Tripal P, Reichel M, Mühle C, Rhein C, Muehlbacher M, Groemer TW, Gulbins E (2010) Functional inhibitors of acid sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem 26:09-20
26. Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, Koka S, Eisele K, Klarl BA, Rubben H, Schmid KW, Mann K, Hildenbrand S, Hefter H, Huber SM, Wieder T, Erhardt A, Haussinger D, Gulbins E, Lang F (2007) Liver cell death and anemia in wilson disease involve acid sphingomyelinase and ceramide. Nat Med 13:164-170
27. Lee DH, Kim SH, Ahn KH, Kim SK, Choi JM, Ji JE, Won JH, Park YH, Lim C, Kim S, Kim DK (2011) Identification and evaluation of neutral sphingomyelinase 2 inhibitors. Arch Pharm Res34:229-236
28. Luberto C, Hannun YA (1998) Sphingomyelin synthase, a potential regulator of intracellular levels of ceramide and diacylglycerol during SV40 transformation. Does sphingomyelin synthase account for the putative phosphatidylcholine-specific phospholipase C? J Biol Chem 273:14550-14559
29. Luberto C, Hassler DF, Signorelli P, Okamoto Y, Sawai H, Boros E, Hazen-Martin DJ, Obeid LM, Hannun YA, Smith GK (2002) Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J Biol Chem 277:41128-41139
30. Mandala SM, Thornton RA, Rosenbach M, Milligan J, Garcia-Calvo M, Bull HG, Kurtz MB (1997) Khafrefungin, a novel inhibitor of sphingolipid synthesis. J Biol Chem 272: 32709- 32714
31. Mandala SM, Thornton RA, Milligan J, Rosenbach M, Garcia-Calvo M, Bull HG, Harris G, Abruzzo GK, Flattery AM, Gill CJ, Bartizal K, Dreikorn S, Kurtz MB (1998) Rustmicin, a potent antifungal agent, inhibits sphingolipid synthesis at inositol phosphoceramide synthase.J Biol Chem 273:14942-14949
32. Nara F, Tanaka M,Masuda-Inoue S, Yamasato Y, Doi-Yoshioka H, Suzuki-Konagai K,Kumakura S, Ojita T (1999) Biological activities of scyphostatin, a neutral sphingomyelinase inhibitor from a discomycete, Trichopeziza mollissima. J Antibiot 52:531-535
33. Platt FM, Neises GR, Dwek RA, Butter TD (1994) N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem 269:8362-8365
34. Raisova M, Goltz G, Bektas M, Bielawska A, Riebeling C, Hossini AM, Eberlea J, Hannun YA, Orfanos CE, Geilen CC (2002) Bcl-2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes. FEBS Lett 516:47-52
35. Riethmü ller J, Anthonysamy J, Emilio Serra E, Schwab M, Do?ring G, Gulbins E (2009) Therapeutic efficacy and safety of amitriptyline in patients with cystic fibrosis. Cell Physiol Biochem 22:405-412
36. Roth AG, Redmer S, Arenz C (2009a) Potent inhibition of acid sphingomyelinase by phosphoinositide analogues. Chembiochem 10:2367-2374
37. Roth AG, Drescher D, Yang Y, Redmer S, Uhlig S, Arenz C (2009b) Potent and selective inhibition of acid sphingomyelinase by bisphosphonates. Angew Chem Int Ed 48:7560- 7563
38. Roth AG, Redmer S, Arenz C (2010) Development of carbohydrate-derived inhibitors of acid sphingomyelinase. Bioorg Med Chem 18:939-944
39. Schuchman E, Desnick RJ (2005) Chaperone-based therapy for Niemann-Pick-disease. US Patent Application Publication, Pub. No.: US 2005/0153934 A1
40. Strelow A, Bernardo K, Adam-Klages S, Linke T, Sandhoff K, Kronke M, Adam D (2000) Overexpression of acid ceramidase protects from tumor necrosis factor-induced cell death.J Exp Med 192:601-612
41. Szulc ZM, Mayroo N, Bai A, Bielawski J, Liu X, Norris JS, Hannun YA, Bielawska A (2008) Novel analogs of d-e-MAPP and B13. Part 1: synthesis and evaluation as potential anticancer agents. Bioorg Med Chem 16:1015-1031
42. Teichgraber V, Ulrich M, Endlich N, Riethmuller J, Wilker B, De Oliveira-Munding CC, van Heeckeren AM, Barr ML, von Kurthy G, Schmid KW, Weller M, Tummler B, Lang F, Grassme H, Doring G, Gulbins E (2008) Ceramide accumulation mediates inflammation, celldeath and infection susceptibility in cystic fibrosis. Nat Med 14:382-391
43. Triola G, Fabrias G, Llebaria A (2001) Synthesis of a cyclopropene analogue of ceramide, a potent inhibitor of dihydroceramide desaturase. Angew Chem Int Ed Engl 40:1960-1962
44. Triola G, Fabrias G, Dragusin M, Niederhausen L, Broere R, Llebaria A, van Echten- eckert G(2004) Specificity of the dihydroceramide desaturase inhibitor N-[(1R,2S)-2-hydroxy-1- hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl) ethyl]o ctanamide (GT11) in primary ultured cerebellar neurons. Mol Pharmacol 66:1671-1678
45. Ueda N, Yamanaka K, Yamamoto S (2001) Purification and characterization of an acid midase selective for N-palmitoylethanolamine, a putative endogenous anti- inflammatory substance.J Biol Chem 276:35552-35557
46. Wascholowski V, Giannis A (2006) Sphingolactones: selective and irreversible inhibitors of neutral sphingomyelinase. Angew Chem Int Ed 45:827-830